Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer
/in Dendritic Cells, International Publications, NSCLC /von 2016-04-21 / Radiat Oncol 2016 Apr;11:60Pilot study of radiofrequency hyperthermia in combination with gefitinib in gefitinib-effective patients with advanced NSCLC
/in Hyperthermia, International Publications, NSCLC /von 2016-03-24 / Thorac Cancer 2016 Jul;7(4):422-7Dendritic cell vaccine and cytokine-induced killer cell therapy for the treatment of advanced non-small cell lung cancer
/in Dendritic Cells, International Publications, NSCLC /von 2016-02-24 / Oncol Lett 2016 Apr;11(4):2605-2610Oncolytic newcastle disease virus triggers cell death of lung cancer spheroids and is enhanced by pharmacological inhibition of autophagy
/in International Publications, Newcastle Disease Virus, NSCLC /von 2015-11-15 / Am J Cancer Res 2015;5(12):3612-23Vaccine immunotherapy in lung cancer: Clinical experience and future directions
/in International Publications, NSCLC, SCLC /von 2015-05-16 / Pharmacol. Ther. 2015 Sep;153:1-9Immunotherapy for lung cancer: for whom the bell tolls?
/in Dendritic Cells, International Publications, NSCLC /von 2015-03-04 / Tumour Biol. 2015 Mar;36(3):1411-22Dendritic cell immunotherapy combined with cytokine-induced killer cells promotes skewing toward Th2 cytokine profile in patients with metastatic non-small cell lung cancer
/in Dendritic Cells, International Publications, NSCLC /von 2015-02-16 / Int. Immunopharmacol. 2015 Apr;25(2):450-6Apoptotic induction of lung adenocarcinoma A549 cells infected by recombinant RVG Newcastle disease virus (rL-RVG) in vitro
/in International Publications, Newcastle Disease Virus, NSCLC /von 2014-10-15 / Mol Med Rep 2015 Jan;11(1):317-26Inhibition of cell proliferation by mild hyperthermia at 43˚C with Paris Saponin I in the lung adenocarcinoma cell line PC-9
/in Hyperthermia, International Publications, NSCLC /von 2014-10-15 / Mol Med Rep 2015 Jan;11(1):327-32
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- From Localized Mild Hyperthermia to Improved Tumor Oxygenation: Physiological Mechanisms Critically Involved in Oncologic Thermo-Radio-Immunotherapy
- Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience
- Immunotherapy in breast cancer: an overview of current strategies and perspectives